Cargando…

Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy

INTRODUCTION: Multiple studies now confirm that ∼40% of patients with fibromyalgia syndrome meet diagnostic criteria for small-fiber polyneuropathy (SFPN) and have objective pathologic or physiologic evidence of SFPN, whereas 60% do not. Given possibilities that tens or hundreds of millions globally...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodahl, Mette, Treister, Roi, Oaklander, Anne Louise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802321/
https://www.ncbi.nlm.nih.gov/pubmed/29430562
http://dx.doi.org/10.1097/PR9.0000000000000633
_version_ 1783298513722933248
author Lodahl, Mette
Treister, Roi
Oaklander, Anne Louise
author_facet Lodahl, Mette
Treister, Roi
Oaklander, Anne Louise
author_sort Lodahl, Mette
collection PubMed
description INTRODUCTION: Multiple studies now confirm that ∼40% of patients with fibromyalgia syndrome meet diagnostic criteria for small-fiber polyneuropathy (SFPN) and have objective pathologic or physiologic evidence of SFPN, whereas 60% do not. Given possibilities that tens or hundreds of millions globally could have SFPN, developing screening tools becomes important. OBJECTIVES: This analysis explored whether specific symptoms might help distinguish these fibromyalgia endophenotypes. METHODS: With institutional review board approval, all adults tested for SFPN by distal-leg skin biopsy or autonomic function testing at Massachusetts General Hospital in 2014 to 2015 were queried about symptoms. Inclusion required a physician's fibromyalgia syndrome diagnosis plus meeting the American College of Rheumatology 2010 Fibromyalgia Criteria. The primary outcome was the validated Small-fiber Symptom Survey, which captures severity of all known SFPN-associated symptoms. The Composite Autonomic Symptom Score-31, Short-Form Health Survey-36, and Short-Form McGill Pain Questionnaires provided secondary outcomes. RESULTS: Among the 39 participants, 14 had test-confirmed SFPN (SFPN+) and 25 did not (SFPN−). Their pain severity did not differ. Paresthesias (“tingling”) were different (worse) in the SFPN+ group (3.14 ± 0.9 vs 2.28 ± 1.1; P = 0.16). Their component subscore for dysautonomia symptoms was also worse (10.42 ± 4.0 vs 7.16 ± 4.0; P = 0.019). Receiver operating characteristic analyses revealed that each item had fair diagnostic utility in predicting SFPN, with areas under the curve of 0.729. No secondary questionnaires discriminated significantly. CONCLUSION: Among patients with fibromyalgia, most symptoms overlap between those with or without confirmed SFPN. Symptoms of dysautonomia and paresthesias may help predict underlying SFPN. The reason to screen for SFPN is because—unlike fibromyalgia—its medical causes can sometimes be identified and definitively treated or cured.
format Online
Article
Text
id pubmed-5802321
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-58023212018-02-09 Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy Lodahl, Mette Treister, Roi Oaklander, Anne Louise Pain Rep Neuropathic INTRODUCTION: Multiple studies now confirm that ∼40% of patients with fibromyalgia syndrome meet diagnostic criteria for small-fiber polyneuropathy (SFPN) and have objective pathologic or physiologic evidence of SFPN, whereas 60% do not. Given possibilities that tens or hundreds of millions globally could have SFPN, developing screening tools becomes important. OBJECTIVES: This analysis explored whether specific symptoms might help distinguish these fibromyalgia endophenotypes. METHODS: With institutional review board approval, all adults tested for SFPN by distal-leg skin biopsy or autonomic function testing at Massachusetts General Hospital in 2014 to 2015 were queried about symptoms. Inclusion required a physician's fibromyalgia syndrome diagnosis plus meeting the American College of Rheumatology 2010 Fibromyalgia Criteria. The primary outcome was the validated Small-fiber Symptom Survey, which captures severity of all known SFPN-associated symptoms. The Composite Autonomic Symptom Score-31, Short-Form Health Survey-36, and Short-Form McGill Pain Questionnaires provided secondary outcomes. RESULTS: Among the 39 participants, 14 had test-confirmed SFPN (SFPN+) and 25 did not (SFPN−). Their pain severity did not differ. Paresthesias (“tingling”) were different (worse) in the SFPN+ group (3.14 ± 0.9 vs 2.28 ± 1.1; P = 0.16). Their component subscore for dysautonomia symptoms was also worse (10.42 ± 4.0 vs 7.16 ± 4.0; P = 0.019). Receiver operating characteristic analyses revealed that each item had fair diagnostic utility in predicting SFPN, with areas under the curve of 0.729. No secondary questionnaires discriminated significantly. CONCLUSION: Among patients with fibromyalgia, most symptoms overlap between those with or without confirmed SFPN. Symptoms of dysautonomia and paresthesias may help predict underlying SFPN. The reason to screen for SFPN is because—unlike fibromyalgia—its medical causes can sometimes be identified and definitively treated or cured. Wolters Kluwer 2017-12-16 /pmc/articles/PMC5802321/ /pubmed/29430562 http://dx.doi.org/10.1097/PR9.0000000000000633 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain. This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0 (CC BY-ND) (http://creativecommons.org/licenses/by-nd/4.0/) which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
spellingShingle Neuropathic
Lodahl, Mette
Treister, Roi
Oaklander, Anne Louise
Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy
title Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy
title_full Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy
title_fullStr Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy
title_full_unstemmed Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy
title_short Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy
title_sort specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy
topic Neuropathic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802321/
https://www.ncbi.nlm.nih.gov/pubmed/29430562
http://dx.doi.org/10.1097/PR9.0000000000000633
work_keys_str_mv AT lodahlmette specificsymptomsmaydiscriminatebetweenfibromyalgiapatientswithvswithoutobjectivetestevidenceofsmallfiberpolyneuropathy
AT treisterroi specificsymptomsmaydiscriminatebetweenfibromyalgiapatientswithvswithoutobjectivetestevidenceofsmallfiberpolyneuropathy
AT oaklanderannelouise specificsymptomsmaydiscriminatebetweenfibromyalgiapatientswithvswithoutobjectivetestevidenceofsmallfiberpolyneuropathy